Kodiak Sciences Inc
NASDAQ:KOD

Watchlist Manager
Kodiak Sciences Inc Logo
Kodiak Sciences Inc
NASDAQ:KOD
Watchlist
Price: 6.19 USD 4.92% Market Closed
Market Cap: 325.7m USD
Have any thoughts about
Kodiak Sciences Inc?
Write Note

Intrinsic Value

KOD's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

The intrinsic value of one KOD stock under the Base Case scenario is 3.76 USD. Compared to the current market price of 6.19 USD, Kodiak Sciences Inc is Overvalued by 39%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

KOD Intrinsic Value
3.76 USD
Overvaluation 39%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Kodiak Sciences Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for KOD cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about KOD?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Kodiak Sciences Inc

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Kodiak Sciences Inc

Provide an overview of the primary business activities
of Kodiak Sciences Inc.

What unique competitive advantages
does Kodiak Sciences Inc hold over its rivals?

What risks and challenges
does Kodiak Sciences Inc face in the near future?

Has there been any significant insider trading activity
in Kodiak Sciences Inc recently?

Summarize the latest earnings call
of Kodiak Sciences Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Kodiak Sciences Inc.

Provide P/S
for Kodiak Sciences Inc.

Provide P/E
for Kodiak Sciences Inc.

Provide P/OCF
for Kodiak Sciences Inc.

Provide P/FCFE
for Kodiak Sciences Inc.

Provide P/B
for Kodiak Sciences Inc.

Provide EV/S
for Kodiak Sciences Inc.

Provide EV/GP
for Kodiak Sciences Inc.

Provide EV/EBITDA
for Kodiak Sciences Inc.

Provide EV/EBIT
for Kodiak Sciences Inc.

Provide EV/OCF
for Kodiak Sciences Inc.

Provide EV/FCFF
for Kodiak Sciences Inc.

Provide EV/IC
for Kodiak Sciences Inc.

Show me price targets
for Kodiak Sciences Inc made by professional analysts.

What are the Revenue projections
for Kodiak Sciences Inc?

How accurate were the past Revenue estimates
for Kodiak Sciences Inc?

What are the Net Income projections
for Kodiak Sciences Inc?

How accurate were the past Net Income estimates
for Kodiak Sciences Inc?

What are the EPS projections
for Kodiak Sciences Inc?

How accurate were the past EPS estimates
for Kodiak Sciences Inc?

What are the EBIT projections
for Kodiak Sciences Inc?

How accurate were the past EBIT estimates
for Kodiak Sciences Inc?

Compare the revenue forecasts
for Kodiak Sciences Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Kodiak Sciences Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Kodiak Sciences Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Kodiak Sciences Inc compared to its peers.

Compare the P/E ratios
of Kodiak Sciences Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Kodiak Sciences Inc with its peers.

Analyze the financial leverage
of Kodiak Sciences Inc compared to its main competitors.

Show all profitability ratios
for Kodiak Sciences Inc.

Provide ROE
for Kodiak Sciences Inc.

Provide ROA
for Kodiak Sciences Inc.

Provide ROIC
for Kodiak Sciences Inc.

Provide ROCE
for Kodiak Sciences Inc.

Provide Gross Margin
for Kodiak Sciences Inc.

Provide Operating Margin
for Kodiak Sciences Inc.

Provide Net Margin
for Kodiak Sciences Inc.

Provide FCF Margin
for Kodiak Sciences Inc.

Show all solvency ratios
for Kodiak Sciences Inc.

Provide D/E Ratio
for Kodiak Sciences Inc.

Provide D/A Ratio
for Kodiak Sciences Inc.

Provide Interest Coverage Ratio
for Kodiak Sciences Inc.

Provide Altman Z-Score Ratio
for Kodiak Sciences Inc.

Provide Quick Ratio
for Kodiak Sciences Inc.

Provide Current Ratio
for Kodiak Sciences Inc.

Provide Cash Ratio
for Kodiak Sciences Inc.

What is the historical Revenue growth
over the last 5 years for Kodiak Sciences Inc?

What is the historical Net Income growth
over the last 5 years for Kodiak Sciences Inc?

What is the current Free Cash Flow
of Kodiak Sciences Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Kodiak Sciences Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Kodiak Sciences Inc

Current Assets 202.5m
Cash & Short-Term Investments 197.9m
Other Current Assets 4.6m
Non-Current Assets 170.2m
PP&E 155.3m
Other Non-Current Assets 14.9m
Current Liabilities 24.1m
Accounts Payable 3.3m
Accrued Liabilities 20.8m
Non-Current Liabilities 163.2m
Other Non-Current Liabilities 163.2m
Efficiency

Earnings Waterfall
Kodiak Sciences Inc

Revenue
0 USD
Operating Expenses
-204m USD
Operating Income
-204m USD
Other Expenses
12.4m USD
Net Income
-191.6m USD

Free Cash Flow Analysis
Kodiak Sciences Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

The company is advancing tarcocimab in two new Phase III studies for diabetic retinopathy and wet AMD, with GLOW2 already enrolling patients and DAYBREAK targeting recruitment by mid-2024. Tarcocimab aims to demonstrate extended durability, improved competitive positioning, and enhanced global regulatory prospects. Additionally, KSI-501, a novel bispecific antibody, is entering Phase III in wet AMD, designed to address the variability in response to current treatments by targeting both VEGF and IL-6 pathways. These developments represent significant progress in addressing unmet needs in retinal vascular diseases.

What is Earnings Call?
Fundamental Scores

KOD Profitability Score
Profitability Due Diligence

Kodiak Sciences Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

27/100
Profitability
Score

Kodiak Sciences Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

KOD Solvency Score
Solvency Due Diligence

Kodiak Sciences Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Low Altman Z-Score
56/100
Solvency
Score

Kodiak Sciences Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

KOD Price Targets Summary
Kodiak Sciences Inc

Wall Street analysts forecast KOD stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for KOD is 4.28 USD with a low forecast of 2.02 USD and a high forecast of 6.3 USD.

Lowest
Price Target
2.02 USD
67% Downside
Average
Price Target
4.28 USD
31% Downside
Highest
Price Target
6.3 USD
2% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for KOD?

Click here to dive deeper.

Dividends

Kodiak Sciences Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for KOD is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

KOD Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

KOD News

Profile

Kodiak Sciences Inc Logo
Kodiak Sciences Inc

Country

United States of America

Industry

Biotechnology

Market Cap

325.7m USD

Dividend Yield

0%

Description

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Palo Alto, California and currently employs 93 full-time employees. The company went IPO on 2018-10-04. The Company’s Antibody Biopolymer Conjugate (ABC) Platform uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies. The Company’s lead product candidate includes KSI-301, which is an antibody biopolymer conjugate being investigated in multiple pivotal studies in retinal vascular diseases, including wAMD, DME, RVO and non-proliferative diabetic retinopathy. KSI-301 is under Phase IIb/III clinical trials. The Company’s other pipeline candidates includes product candidates KSI-501 and KSI-601, which are developed for the treatment of other unmet needs in retina, such as dry AMD and glaucoma. The Company’s subsidiary includes Kodiak Sciences GmbH.

Contact

CALIFORNIA
Palo Alto
1200 Page Mill Rd
+16502810850.0
kodiak.com

IPO

2018-10-04

Employees

93

Officers

Co-Founder, Chairman, CEO & President
Dr. Victor Perlroth M.D.
Executive VP, CFO & Secretary
Mr. John A. Borgeson CPA, M.B.A.
Chief Scientific Officer
Dr. Dolly S. Chang M.D., M.P.H., Ph.D.
Senior Vice President of Development
Dr. Hong Liang Ph.D.
Senior Vice President of Chemical Development & Manufacturing
Dr. Stephen Raillard Ph.D.
Chief Quality Officer
Ms. Almas Qudrat M.Sc.
Show More
Chief Medical Officer
Dr. J. Pablo Velazquez-Martin M.D.
VP & Corporate Controller
Ms. Tracy Chien
Show Less

See Also

Discover More
What is the Intrinsic Value of one KOD stock?

The intrinsic value of one KOD stock under the Base Case scenario is 3.76 USD.

Is KOD stock undervalued or overvalued?

Compared to the current market price of 6.19 USD, Kodiak Sciences Inc is Overvalued by 39%.

Back to Top